Benefits
Joint pain reduction at ultra-low 20 mg dose
An 8-week clinical study confirmed Q-Actin® at just 20 mg/day significantly reduced mild-to-moderate joint pain in adults, supporting mobility and joint comfort. This dose efficiency — 20 mg vs. 1,500 mg for glucosamine or 2,000–4,000 mg for collagen — makes Q-Actin® exceptionally valuable for capsule and tablet formulations where joint health ingredient doses typically dominate the formula.
Anti-inflammatory joint support
Cucumber cucurbitacins (tetracyclic triterpenoids) inhibit COX-2 enzyme and suppress pro-inflammatory prostaglandin production — providing anti-inflammatory joint protection through the same pathway as NSAIDs but from a food-derived natural botanical source. The combination of cucurbitacins and hydroxycinnamic acids (caffeic acid, coumaric acid) in Q-Actin® provides complementary anti-inflammatory mechanisms.
Mobility and functional improvement
The clinical study confirmed that beyond pain reduction, Q-Actin® supplementation improved functional mobility metrics — range of motion, ease of movement, and ability to perform daily activities — reflecting genuine joint function improvement rather than only symptom masking.
Mechanism of action
Cucurbitacin COX-2 inhibition and hydroxycinnamic acid anti-inflammatory activity
Q-Actin®'s standardized cucurbitacins inhibit NF-κB nuclear translocation and downstream COX-2 enzyme expression — reducing prostaglandin E2 (PGE2) production that sensitizes pain receptors and drives synovial inflammation. Caffeic acid and other hydroxycinnamic acids in the cucumber extract provide complementary 5-LOX inhibition and free radical scavenging, addressing multiple inflammatory pathways relevant to joint pain and degradation simultaneously.
Clinical trials
Clinical study examining Q-Actin® (20 mg/day cucumber extract) effects on mild-to-moderate joint pain and mobility over 8 weeks. Note: full peer-reviewed publication for Q-Actin®-specific trials may be limited; primary documentation through manufacturer (ChromaDex/InvivoCue).
80 adults (mean age 50.10) with mild-to-moderate joint pain (>3 months history). Randomized, double-blind, placebo-controlled trial; 20 mg/day Q-actin™ (Cucumis sativus L. standardized to >1% idoBR1 iminosugar) or matching placebo for 60 days. NCT06246383 (Jacksonville University). Funded in part by Gateway Health.
Significant Q-actin improvements emerged by Day 30 and strengthened to Day 60: WOMAC pain, stiffness, and function all improved vs placebo. Brief Pain Inventory and Pain Disability Index also improved. Supports earlier trial (n=122 vs glucosamine-chondroitin, 180 days) showing 20 mg Q-actin twice daily was non-inferior to 1,350 mg glucosamine-chondroitin twice daily for moderate knee OA. Mechanism: idoBR1 reduces LPS-induced TNFα, IL-6, NO, and NF-κB. Effective at very low dose (20 mg/day) compared to typical 1,500 mg+ chondroprotectant doses.